DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095 Bakhoum, 2018, Chromosomal instability drives metastasis through a cytosolic DNA response, Nature, 553, 467, 10.1038/nature25432 Boland, 2010, Microsatellite instability in colorectal cancer, Gastroenterology, 138, 2073, 10.1053/j.gastro.2009.12.064 Chan, 2015, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 373, 1984, 10.1056/NEJMc1508163 Chang, 2018, Immune profiling of premalignant lesions in patients with Lynch syndrome, JAMA Oncol., 4, 1085, 10.1001/jamaoncol.2018.1482 Cho, 2000, Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells, J. Exp. Med., 192, 549, 10.1084/jem.192.4.549 Cristescu, 2018, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy, Science, 362, eaar3593, 10.1126/science.aar3593 Deng, 2014, STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors, Immunity, 41, 843, 10.1016/j.immuni.2014.10.019 Der, 1998, Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays, Proc. Natl. Acad. Sci. U S A, 95, 15623, 10.1073/pnas.95.26.15623 Diaz, 2017, Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers, Ann. Oncol., 28, abstr 386P Dunn, 2006, Interferons, immunity and cancer immunoediting, Nat. Rev. Immunol., 6, 836, 10.1038/nri1961 Ganesh, 2019, Immunotherapy in colorectal cancer: rationale, challenges and potential, Nat. Rev. Gastroenterol. Hepatol., 16, 361, 10.1038/s41575-019-0126-x Germano, 2017, Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, Nature, 552, 116, 10.1038/nature24673 Ghandi, 2019, Next-generation characterization of the Cancer Cell Line Encyclopedia, Nature, 569, 503, 10.1038/s41586-019-1186-3 Guan, 2021, MLH1 deficiency-triggered DNA hyperexcision by exonuclease 1 activates the cGAS-STING pathway, Cancer Cell, 10.1016/j.ccell.2020.11.004 Hartman, 2005, Global changes in STAT target selection and transcription regulation upon interferon treatments, Genes Dev., 19, 2953, 10.1101/gad.1371305 Heemskerk, 2013, The cancer antigenome, EMBO J., 32, 194, 10.1038/emboj.2012.333 Indraccolo, 2007, Identification of genes selectively regulated by IFNs in endothelial cells, J. Immunol., 178, 1122, 10.4049/jimmunol.178.2.1122 Joffre, 2012, Cross-presentation by dendritic cells, Nat. Rev. Immunol., 12, 557, 10.1038/nri3254 Koelzer, 2012, Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status, J. Clin. Pathol., 65, 996, 10.1136/jclinpath-2012-200742 Kopetz, 2018, Cancer Res., 78, 2603, 10.1158/1538-7445.AM2018-2603 Kwon, 2020, The cytosolic DNA-sensing cGAS-STING pathway in cancer, Cancer Discov., 10, 26, 10.1158/2159-8290.CD-19-0761 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science, 357, 409, 10.1126/science.aan6733 Lemos, 2016, STING promotes the growth of tumors characterized by low antigenicity via IDO activation, Cancer Res., 76, 2076, 10.1158/0008-5472.CAN-15-1456 Li, 2008, Mechanisms and functions of DNA mismatch repair, Cell Res, 18, 85, 10.1038/cr.2007.115 Li, 2019, NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance, Nat. Commun., 10, 3251, 10.1038/s41467-019-11238-1 Liu, 2012, Systematic identification of type I and type II interferon-induced antiviral factors, Proc. Natl. Acad. Sci. U S A, 109, 4239, 10.1073/pnas.1114981109 Liu, 2018, Nuclear cGAS suppresses DNA repair and promotes tumorigenesis, Nature, 563, 131, 10.1038/s41586-018-0629-6 Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov., 5, 43, 10.1158/2159-8290.CD-14-0863 von Loga, 2020, Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer, Nat. Commun., 11, 139, 10.1038/s41467-019-13915-7 Mandal, 2019, Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response, Science, 364, 485, 10.1126/science.aau0447 Marabelle, 2020, Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study, J. Clin. Oncol., 38, 1, 10.1200/JCO.19.02105 Mardjuki, 2020, Development of cGAMP-Luc, a sensitive and precise coupled enzyme assay to measure cGAMP in complex biological samples, J. Biol. Chem., 295, 4881, 10.1074/jbc.RA119.012170 Mariathasan, 2018, TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Modrich, 1996, Mismatch repair in replication fidelity, genetic recombination, and cancer biology, Annu. Rev. Biochem., 65, 101, 10.1146/annurev.bi.65.070196.000533 Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9 Pantelidou, 2019, PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer, Cancer Discov., 9, 722, 10.1158/2159-8290.CD-18-1218 Paz-Ares, 2019, LBA80Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407, Ann. Oncol., 30, 10.1093/annonc/mdz394.078 Peng, 2015, Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy, Nature, 527, 249, 10.1038/nature15520 Peng, 2016, Loss of PTEN promotes resistance to T cell-mediated immunotherapy, Cancer Discov., 6, 202, 10.1158/2159-8290.CD-15-0283 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Sanda, 2006, Differential gene induction by type I and type II interferons and their combination, J. Interferon Cytokine Res., 26, 462, 10.1089/jir.2006.26.462 Sceneay, 2019, Interferon signaling is diminished with age and is associated with immune checkpoint blockade efficacy in triple-negative breast cancer, Cancer Discov., 9, 1208, 10.1158/2159-8290.CD-18-1454 Sen, 2019, Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer, Cancer Discov., 9, 646, 10.1158/2159-8290.CD-18-1020 Shen, 2019, PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness, Cancer Res., 79, 311, 10.1158/0008-5472.CAN-18-1003 Shin, 2017, Primary resistance to PD-1 blockade mediated by JAK1/2 mutations, Cancer Discov., 7, 188, 10.1158/2159-8290.CD-16-1223 Sistigu, 2014, Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy, Nat. Med., 20, 1301, 10.1038/nm.3708 Spranger, 2015, Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, 523, 231, 10.1038/nature14404 Spranger, 2016, Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma, Proc. Natl. Acad. Sci. U S A, 113, E7759, 10.1073/pnas.1609376113 Tang, 2016, Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade, Cancer Cell, 30, 500, 10.1016/j.ccell.2016.08.011 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 Vareki, 2018, High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors, J. Immunother. Cancer, 6, 157, 10.1186/s40425-018-0479-7 Vasaikar, 2019, Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities, Cell, 177, 1035, 10.1016/j.cell.2019.03.030 Wang, 2017, cGAS is essential for the antitumor effect of immune checkpoint blockade, P Natl. Acad. Sci. U S A, 114, 1637, 10.1073/pnas.1621363114 Woo, 2014, STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors, Immunity, 41, 830, 10.1016/j.immuni.2014.10.017 Zhang, 2005, Reconstitution of 5′-directed human mismatch repair in a purified system, Cell, 122, 693, 10.1016/j.cell.2005.06.027